- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.07. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 12 | SEC Filings | ||
| CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.07. | Calidi Gains on Company Update | 20 | Baystreet.ca | ||
| 21.07. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers | 3.804 | GlobeNewswire (Europe) | Company receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first patient... ► Artikel lesen | |
| 20.07. | Calidi Biotherapeutics, Inc: Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 | 269 | GlobeNewswire (Europe) | SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE American: CLDI), a biotechnology company pioneering the development of targeted genetic... ► Artikel lesen | |
| 16.07. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 | 2 | GlobeNewswire (USA) | ||
| 24.06. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit | 1 | GlobeNewswire (USA) | ||
| 23.06. | Calidi Biotherapeutics appoints Corsee Sanders to board | 1 | Investing.com | ||
| 23.06. | Calidi Biotherapeutics beruft Corsee Sanders in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 18.06. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study | 128 | GlobeNewswire (Europe) | SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic... ► Artikel lesen | |
| 05.06. | RedChip Companies, Inc.: Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9 | 524 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / June 5, 2026 / RedChip Companies will host an investor webinar with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) ("Calidi" or "the Company") on June 9, 2026, at... ► Artikel lesen | |
| 29.05. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 26.05. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 23.05. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Provides Required NYSE American Disclosure | 237 | GlobeNewswire (Europe) | SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines... ► Artikel lesen | |
| 14.05. | Calidi BioTherapeutics GAAP EPS of -$0.43 | 1 | Seeking Alpha | ||
| 14.05. | Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights | 292 | GlobeNewswire (Europe) | Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end... ► Artikel lesen | |
| 08.05. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.04. | Calidi presents cancer therapy data at AACR meeting | 3 | Investing.com |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,70 | +3,33 % | BioNTech SE und Emyria Limited: Wenn schlafende Biotech-Riesen erwachen und datenstarke Plattformen den Markt erobern | ||
| MEDIGENE | 0,007 | +2,86 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| MODERNA | 51,36 | +0,37 % | Moderna startet Phase-1-Studie mit Ebola-Impfstoffkandidat | Moderna hat eine Phase-1-Studie mit seinem Impfstoffkandidaten mRNA-1469 gegen das Bundibugyo-Ebolavirus (BDBV) begonnen. Nach der Genehmigung durch die kanadische Gesundheitsbehörde wurden in Kanada... ► Artikel lesen | |
| NOVAVAX | 6,850 | -0,29 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| BIOGEN | 178,40 | -0,82 % | Biogen Inc.: Biogen Completes Acquisition of RayThera Inc. | Lead program now in Phase 1 developmentCAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,430 | +0,32 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 7,770 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| AAP IMPLANTATE | 1,580 | 0,00 % | EQS-HV: aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: aap Implantate AG
/ Bekanntmachung der Einberufung zur Hauptversammlung
aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Berlin... ► Artikel lesen | |
| CLINUVEL | 5,666 | -1,05 % | Clinuvel Pharmaceuticals Limited: CLINUVEL implements strategic reorganisation to refocus on U.S. markets | MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce... ► Artikel lesen | |
| BIO-GATE | 2,800 | -3,45 % | EQS-DD: Bio-Gate AG: Karl Richter, Gewährung von 931.201 Bezugsrechten im Rahmen einer Bezugsrechtskapitalerhöhung. | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
05.08.2026 / 09:48... ► Artikel lesen | |
| EDITAS MEDICINE | 2,550 | +2,41 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| ABIVAX | 113,90 | +3,64 % | EQS-News: ABIVAX: Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod | EQS-News: ABIVAX
/ Key word(s): Regulatory Admission
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
30.07.2026 / 22:05 CET/CEST
The issuer... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,236 | +0,98 % | Stocks in Play: Cardiol Therapeutics Inc. | ||
| NEUROCRINE BIOSCIENCES | 142,70 | +0,96 % | Neurocrine Biosciences Commences Phase 1 First-in-human Clinical Study Of NBIP-'1968 | WASHINGTON (dpa-AFX) - Friday, Neurocrine Biosciences, Inc. (NBIX) announced the commencement of a Phase 1 first-in-human clinical study, evaluating the safety and tolerability of NBIP-'1968... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,560 | -0,39 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen |
Das Unternehmen CALIDI BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,070 (+4,43 %) liegt der Kurs bei 1,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALIDI BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.